title: Prognostic importance of scintigraphic left ventricular cavity dilation during intravenous dipyridamole technetium-99m sestamibi myocardial tomographic imaging in predicting coronary events.
abstract: Left ventricular (LV) cavity dilation during stress myocardial perfusion imaging has been associated with multivessel disease, and may be an independent prognostic marker in addition to perfusion defects. The present study examines the predictive value for future cardiac events of transient or fixed LV dilation during dipyridamole technetium-99m (Tc-99m) sestamibi single-photon emission computed tomography (SPECT) imaging. The study included 512 consecutive patients who underwent SPECT imaging with Tc-99m sestamibi after dipyridamole infusion. Transient LV dilation was seen in 70 patients (14%) and 74 had fixed cavity dilation (14%); cavity size was normal in 368 patients (72%). Each perfusion scan was classified as normal or abnormal, and if abnormal, defects were categorized as transient or fixed, and as small, medium, or large (depending upon the number of abnormal vascular territories). Events during a mean follow-up of 12.8 +/- 6.8 months were tabulated by direct review of hospital charts and death certificates. The cardiac event rate (cardiac death or nonfatal infarction) was 1.9% in patients with normal cavity size, 11.4% with transient LV dilation, and 13.5% with fixed LV dilation (p < 0.01). Compared with patients with normal cavity size, those with transient LV dilation were more likely to sustain a myocardial infarction (p < 0.01) and those with fixed dilation more frequently suffered cardiac death (p < 0.01) and hospitalization for heart failure (p < 0.01). The group with the highest risk had both a large perfusion defect and cavity dilation. By Cox proportional hazard regression analysis, both transient and fixed LV dilation were strong independent predictors of cardiac events. Transient or fixed LV dilation are commonly seen during dipyridamole Tc-99m sestamibi SPECT imaging (14% incidence for each) and are useful predictors of cardiac events.
authors.affiliation: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19010, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: McClellan
authors.forename: M I
authors.initials: MI
authors.lastname: Travin
authors.forename: S D
authors.initials: SD
authors.lastname: Herman
authors.forename: J I
authors.initials: JI
authors.lastname: Baron
authors.forename: R J
authors.initials: RJ
authors.lastname: Golub
authors.forename: J J
authors.initials: JJ
authors.lastname: Gallagher
authors.forename: D
authors.initials: D
authors.lastname: Waters
authors.forename: G V
authors.initials: GV
authors.lastname: Heller
mesh_terms: D000368:Aged; D002303:Cardiac Output, Low / Q000209:etiology; D003326:Coronary Circulation; D003327:Coronary Disease / Q000150:complications; D003331:Coronary Vessels / Q000000981:diagnostic imaging; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004108:Dilatation, Pathologic / Q000150:complications / Q000000981:diagnostic imaging; D004176:Dipyridamole / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006331:Heart Diseases / Q000150:complications / Q000000981:diagnostic imaging*; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006760:Hospitalization; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology*; D011379:Prognosis; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D017256:Technetium Tc 99m Sestamibi / Q000008:administration & dosage; D015899:Tomography, Emission-Computed, Single-Photon; D014665:Vasodilator Agents / Q000008:administration & dosage
chemical_list: D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi